|
ISTA Pharmaceuticals, Inc. is a rapidly growing specialty pharmaceutical company and is the fourth largest branded ophthalmic pharmaceutical business in the U.S., according to data provided by IMS Health. Our products address key segments of the $5.5 billion ophthalmic pharmaceutical market and the $2.2 billion nasal allergy market.
ISTA currently markets four products in the United States: Bepreve®(bepotastine besilate ophthalmic solution) for the treatment of itching associated with signs and symptoms of allergic conjunctivitis, Xibrom (bromfenac ophthalmic solution)® for the treatment of inflammation and pain following cataract surgery, Istalol® (timolol maleate ophthalmic solution) for the treatment of glaucoma, and Vitrase ® (hyaluronidase injection) for use as a spreading agent. ISTA also has several allergy and eye product candidates in various stages of development. ISTA Pharmaceuticals, Inc. had 2009 revenues of $111 million and is based in Irvine, California.
ISTA is organized as a Delaware corporation. The company is a NASDAQ-listed company under the symbol ISTA. Our principal executive offices are located at 15295 Alton Parkway, Irvine, CA 92618, and ISTA’s telephone number is (949) 788-6000.
Company Timeline
| February 1992 |
Founded as Advanced Corneal Systems |
| March 2000 |
Name change to ISTA Pharmaceuticals, Inc.
|
| August 2000 |
IPO, shares begin trading on NASDAQ
|
| May 2002 |
Acquired Assets of AcSentient, Inc.
Istalol® (Senju)
Xibrom® (Senju)
|
| May 2004 |
FDA approval of Vitrase
Q1 2005 Launch of Vitrase
|
| June 2004 |
FDA approval of Istalol
Q3 2004 Launch of Istalol
|
| March 2005 |
FDA approval of Xibrom
Q2 2005 Launch of Xibrom
|
| September 2009 |
FDA approval of BEPREVE
Q4 2009 Launch of Bepreve
|
| 2009 |
Company revenues exceed $100 million
|
|
